Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: A longitudinal study of 3035 patients

American Journal of Medicine

Volumn 115, Issue 5, 2003, Pages 371-376

  Krishnan, Eswar ^a,b   Fries, James F ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Clinical Research Center of Reading   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISABILITY; DISEASE DURATION; EDUCATION; FOLLOW UP; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; GENDER; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RACE; RHEUMATOID ARTHRITIS; CLINICAL TRIAL; COHORT ANALYSIS; DAILY LIFE ACTIVITY; FEMALE; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; REGRESSION ANALYSIS;

ACTIVITIES OF DAILY LIVING; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DISABILITY EVALUATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS;

EID: 0142243119     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(03)00397-8     Document Type: Article

References (47)

1. A randomized trial of hydroxychloroquine in early rheumatoid arthritis the HERA Study . Am J Med. 98:1995;156-168.
2. Davis M.J., Dawes P.T., Fowler P.D., et al. Should disease-modifying agents be used in mild rheumatoid arthritis? Br J Rheumatol. 30:1991;451-454.
3. Hannonen P., Mottonen T., Hakola M., Oka M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum. 36:1993;1501-1509.
4. Sulfasalazine in early rheumatoid arthritis. J Rheumatol. 19:1992;1672-1677.
5. Jones G., Halbert J., Crotty M., et al. The effect of treatment on radiological progression in rheumatoid arthritis a systematic review of randomized placebo-controlled trials . Rheumatology. 42:2003;6-13.
6. Felson D.T., Anderson J.J., Meenan R.F. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two meta-analyses . Arthritis Rheum. 33:1990;1449-1461.
7. Egsmose C., Lund B., Borg G., et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy 5 year followup of a prospective double blind placebo controlled study . J Rheumatol. 22:1995;2208-2213.
8. Munro R., Hampson R., McEntegart A., et al. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold results of a five year prospective study . Ann Rheum Dis. 57:1998;88-93.
9. Tsakonas E., Fitzgerald A.A., Fitzcharles M.A., et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis a 3 year followup on the Hydroxychloroquine in Early Rheumatoid Arthritis (HERA) study . J Rheumatol. 27:2000;623-629.
10. van der Heide A., Jacobs J.W., Bijlsma J.W., et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med. 124:1996;699-707.
11. Houssien D.A., Scott D.L. Early referral and outcome in rheumatoid arthritis. Scand J Rheumatol. 27:1998;300-302.
12. Pincus T. The paradox of effective therapies but poor long-term outcomes in rheumatoid arthritis. Semin Arthritis Rheum. 21:1992;2-15.
13. Sokka T., Mottonen T., Hannonen P. Disease-modifying anti-rheumatic drug use according to the "sawtooth" treatment strategy improves the functional outcome in rheumatoid arthritis results of a long-term follow-up study with review of the literature . Rheumatology (Oxf). 39:2000;34-42.
14. Ward M.M. Trends in the use of disease modifying antirheumatic medications in rheumatoid arthritis, 1980-1995 results from the National Ambulatory Medical Care Surveys . J Rheumatol. 26:1999;546-550.
15. Krishnan E., Fries J.F. Time trends in cumulative disability in rheumatoid arthritis 1960-1998. Arthritis Rheum. 44:(suppl):2001;S378.
16. Singh G. Arthritis, Rheumatism and Aging Medical Information System Post- Marketing Surveillance Program. J Rheumatol. 28:2001;1174-1179.
17. Ropes M.W., Bennett G.A., Cobb S., Jacox R., Jessar R.A. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 9:1958;175-176.
18. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:1988;315-324.
19. Fries J.F., Spitz P., Kraines R.G., Holman H.R. Measurement of patient outcome in arthritis. Arthritis Rheum. 23:1980;137-145.
20. Hawley D.J., Wolfe F. Sensitivity to change of the health assessment questionnaire and other clinical and health status measures in rheumatoid arthritis results of short-term clinical trials and observational studies versus long-term observational studies . Arthritis Care Res. 5:1992;130-136.
21. Bruce B., Fries J.F. The Stanford Health Assessment Questionnaire a review of its history, issues, progress, and documentation . J Rheumatol. 30:2003;167-178.
22. Kosinski M., Zhao S.Z., Dedhiya S., et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 43:2000;1478-1487.
23. Fries J.F., Spitz P.W., Young D.Y. The dimensions of health outcomes the health assessment questionnaire, disability and pain scales . J Rheumatol. 9:1982;789-793.
24. The National Death Index (NDI). National Center for Health Statistics. Available at: http://www.cdc.gov/nchs/r&d/ndi.htm. Accessed February 22, 2002.
25. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1:1986;307-310.
26. Maddala G.S. Introduction to Econometric Analysis. 1992;Macmillan, New York, New York.
27. College Station. 2001;Stata Corporation, Texas.
28. Balatagi B., Wu P.X. Unequally spaced panel data regressions with AR(1) disturbances. Econ Theory. 15:1999;814-823.
29. Kent J. Robust properties of likelihood ratio tests. Biometrika. 69:1982;19-27.
30. Clayton D., Hills M. Statistical Models in Epidemiology. 1993;Oxford University Press, Oxford, United Kingdom.
31. Gould W. Jacknife estimation. Stata Tech Bull. 24:1995;25-29.
32. Silman A.J. Trends in the incidence and severity of rheumatoid arthritis. J Rheumatol Suppl. 32:1992;71-73.
33. Doran M.F., Pond G.R., Crowson C.S., O'Fallon W.M., Gabriel S.E. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 46:2002;625-631.
34. Silman A., Davies P., Currey H.L., Evans S.J. Is rheumatoid arthritis becoming less severe? J Chronic Dis. 36:1983;891-897.
35. Enzer I., Dunn G., Jacobsson L., et al. An epidemiologic study of trends in prevalence of rheumatoid factor seropositivity in Pima Indians evidence of a decline due to both secular and birth-cohort influences . Arthritis Rheum. 46:2002;1729-1734.
36. Fries J.F. Reevaluating the therapeutic approach to rheumatoid arthritis the "sawtooth" strategy . J Rheumatol Suppl. 22:1990;12-15.
37. Wilske K.R., Healey L.A. Remodeling the pyramid - a concept whose time has come. J Rheumatol. 16:1989;565-567.
38. Pincus T., Callahan L.F. Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis - lessons from Hodgkin's disease and coronary artery disease. J Rheumatol. 17:1990;1582-1585.
39. Ward M.M., Fries J.F. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996. J Rheumatol. 25:1998;408-416.
40. Manton K.G., Gu X. Changes in the prevalence of chronic disability in the United States black and non-black population above age 65 from 1982 to 1999. Proc Natl Acad Sci. 98:2001;6354-6359.
41. Fries J.F. Reducing disability in older age. JAMA. 288:2002;3164-3166.
42. Sokka T., Krishnan E., Hakkinen A., Hannonen P. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum. 48:2003;59-63.
43. Wang B.W.E., Wolfe F., Fries J.F. Reduction in cumulative disability with increasing exposure to methotrexate in rheumatoid arthritis. Arthritis Rheum. 42:1999;S380.
44. Criswell L.A., Saag K.G., Sems K.M., et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev. 2:2000;CD001158.
45. Wolfe F., Mitchell D.M., Sibley J.T., et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 37:1994;481-494.
46. Barrett E.M., Scott D.G., Wiles N.J., Symmons D.P. The impact of rheumatoid arthritis on employment status in the early years of disease a UK community-based study . Rheumatology (Oxf). 39:2000;1403-1409.
47. Brook A., Fleming A., Corbett M. Relationship of radiological change to clinical outcome in rheumatoid arthritis. Ann Rheum Dis. 36:1977;274-275.